SCHEMBL9918562

SCHEMBL9918562

CN1C(=O)COc2ccc(Nc3c(C(N)=O)nnc4[nH]ccc34)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.47
GRM4 Q14833 1/20 0.44
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
PTGER3 P43115 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
MALT1 Q9UDY8 1/20 0.37
POLB P06746 1/20 0.35
USP30 Q70CQ3 1/20 0.33
PRKCQ Q04759 1/20 0.33
TSHR P16473 1/20 0.33
LRRK2 Q5S007 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
SLC6A4 P31645 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9921977 0.81 ALDH1A1 (0.47) POLBTSHRL3MBTL1
SCHEMBL9921974 0.80 ALDH1A1 (0.44) SYKPOLBHTR1ASLC6A4
SCHEMBL9918555 0.79 SYK (0.36) SYKPOLBLRRK2HTR1ASLC6A4
SCHEMBL9918556 0.75 ALDH1A1 (0.36) POLBTSHRL3MBTL1
SCHEMBL9921982 0.74 KDM4E (0.44) SYKPDE3BPDE3APOLBLRRK2
SCHEMBL9918560 0.73 JAK2 (0.34) SYKLRRK2KCNH2
SCHEMBL9918557 0.71 LRRK2 (0.33) SYKLRRK2
SCHEMBL9921975 0.71 ALDH1A1 (0.34) POLBL3MBTL1
SCHEMBL12833307 0.70 LRRK2 (0.43) SYKLRRK2KCNH2
SCHEMBL9920244 0.70 SYK (0.52) SYKGRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors JAK2, JAK1, JAK3 SYK 87/4885GRM4 4084/4885GABRG2 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.